Prevalence of HIV and Hepatitis B virus co-infection in Sub-Saharan Africa and the potential impact and program feasibility of Hepatitis B surface antigen screening in resource-limited settings

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue , 2015, Pages S274-S285

  Stabinski, Lara ^a   O'Connor, Siobhan ^b   Barnhart, Matthew ^c   Kahn, Rebecca J ^a   Hamm, Tiffany E ^d,e  

^a U S DEPARTMENT OF STATE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

hepatitis B surface antigen; hepatitis B virus; HIV HBV co infection; rapid strip assay; resource limited setting

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; ANTIRETROVIRUS AGENT; TEST STRIP;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; ARTICLE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MIXED INFECTION; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRAM FEASIBILITY; SCREENING TEST; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE PLANNING; HEALTH IMPACT ASSESSMENT; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MASS SCREENING; QUALITY OF LIFE; TEST STRIP;

AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; COINFECTION; COST-BENEFIT ANALYSIS; HEALTH IMPACT ASSESSMENT; HEALTH RESOURCES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; MASS SCREENING; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; REAGENT STRIPS;

EID: 84929077590     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000496     Document Type: Article

References (98)

1. Garfein RS, Vlahov D, Galai N., et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655-661
2. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B coinfection in Asia and Africa. Lancet Infect Dis. 2007;7:402-409
3. Gilson RJ, Hawkins AE, Beecham MR., et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11:597-606
4. van Houdt R, Bruisten SM, Speksnijder AG., et al. Unexpectedly high proportion of drug users and men having sex with men who develop chronic hepatitis B infection. J Hepatol. 2012;57:529-533
5. Thio CL, Seaberg EC, Skolasky R Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921-1926
6. Chun HM, Roediger MP, Hullsiek KH., et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis. 2012;205:185-193
7. Teira R, Group VS. Hepatitis-B virus infection predicts mortality of HIV and hepatitis C virus coinfected patients. AIDS. 2013;27:845-848
8. Salmon-Ceron D, Lewden C, Morlat P., et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799-805
9. Weber R, Sabin CA, Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-1641
10. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. J Hepatol. 2009;49(5 suppl):S138-S145
11. Scharschmidt BF, Held MJ, Hollander HH., et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med. 1992;117:837-838
12. Sinicco A, Raiteri R, Sciandra M., et al. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis. 1997;29:111-115
13. Solomon RE, VanRaden M, Kaslow RA., et al. Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection. Am J Public Health. 1990;80:1475-1478
14. Ockenga J, Tillmann HL, Trautwein C., et al. Hepatitis B and C in HIVinfected patients. Prevalence and prognostic value. J Hepatol. 1997;27: 18-24
15. Hoffmann CJ, Seaberg EC, Young S., et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS. 2009;23:1881-1889
16. Wandeler G, Gsponer T, Bihl F., et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis. 2013;208:1454-1458
17. Bessesen M, Ives D, Condreay L., et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis. 1999;28:1032-1035
18. Pillay D, Cane PA, Ratcliffe D., et al. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee. AIDS. 2000;14: 1111-1116
19. Bellini C, Keiser O, Chave JP., et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med. 2009;10:12-18
20. Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Semin Liver Dis. 2012;32:147-157
21. Kaplan JE, Hamm TE, Forhan S., et al. The impact of HIV care and support interventions on key outcomes in low and middle-income countries: A literature review-introduction. J Acquir Immune Defic Syndr. 2015;68(suppl 3):S253-S256
22. Salmon-Ceron D, Rosenthal E, Lewden C., et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIVinfected patients: The French national Mortalite 2005 study. J Hepatol. 2009;50:736-745
23. Day SL, Odem-Davis K, Mandaliya KN., et al. Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy. PLoS One. 2013;8:e59346
24. Hoffmann CJ, Charalambous S, Martin DJ., et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47:1479-1485
25. Matthews GV, Manzini P, Hu Z., et al. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS. 2011;25:1727-1735
26. Moore E, Beadsworth MB, Chaponda M., et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect. 2010;61:155-163
27. Boyd A, Lasnier E, Molina JM., et al. Liver fibrosis changes in HIV-HBVcoinfected patients: clinical, biochemical and histological effect of longterm tenofovir disoproxil fumarate use. Antivir Ther. 2010;15:963-974
28. de Vries-Sluijs TE, Reijnders JG, Hansen BE., et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology. 2010;139: 1934-1941
29. Dore GJ, Soriano V, Rockstroh J., et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS. 2010;24:857-865
30. Martin-Carbonero L, Teixeira T, Poveda E., et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73-79
31. Zoutendijk R, Zaaijer HL, de Vries-Sluijs TE., et al. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infec Dis. 2012;206:974-980
32. Appiah L, Foster G, Cozzi LA., et al. The burden of liver disease in HIV/HBV co-infected patients accessing antireroviral therapy in Ghana: The HEPIK study. HIV Med. 2012;13:43
33. Avihingsanon A, Matthews GV, Lewin SR., et al. Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand. AIDS Res Ther. 2012;9:6
34. Ayuk J, Mphahlele J, Bessong P. Hepatitis B virus in HIV-infected patients in northeastern South Africa: prevalence, exposure, protection and response to HAART. S Afr Med J. 2013;103:330-333
35. Firnhaber C, Chen CY, Evans D., et al. Prevalence of hepatitis B virus (HBV) co-infection in HBV serologically-negative South African HIV patients and retrospective evaluation of the clinical course of mono- and co-infection. Int J Infect Dis. 2012;16:e268-e272
36. Hawkins C, Agbaji O, Ugoagwu P., et al. Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria. Clin Infect Dis. 2013;57:e189-e192
37. Ladep NG, Agaba PA, Agbaji O., et al. Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World J Gastroenterol. 2013;19:1602-1610
38. Matthews GV, Ali RJ, Avihingsanon A., et al. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. PLoS One. 2013;8:e61297
39. Mayaphi SH, Roussow TM, Masemola DP., et al. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. S Afr Med J. 2012;102(3 pt 1):157-162
40. Mendes-Correa MC, Pinho JR, Gomes-Gouvea MS., et al. Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil. BMC Infect Dis. 2011; 11:247
41. Davies J, van Oosterhout JJ, Nyirenda M., et al. Reliability of rapid testing for hepatitis B in a region of high HIV endemicity. Trans R Soc Trop Med Hyg. 2010;104:162-164
42. Franzeck FC, Ngwale R, Msongole B., et al. Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania. PLoS One. 2013;8:e58468
43. Maity S, Nandi S, Biswas S., et al. Performance and diagnostic usefulness of commercially available enzyme linked immunosorbent assay and rapid kits for detection of HIV, HBV and HCV in India. Virol J. 2012;9:290
44. Nyirenda M, Beadsworth MB, Stephany P., et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect. 2008;57:72-77
45. Scheiblauer H, El-Nageh M, Diaz S., et al. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang. 2010;98(3 pt 2):403-414
46. Seremba E, Ocama P, Opio CK., et al. Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda. J Med Virol. 2010;82:1334-1340
47. Ramos JM, Toro C, Reyes F., et al. Seroprevalence of HIV-1, HBV, HTLV-1 and Treponema pallidum among pregnant women in a rural hospital in Southern Ethiopia. J Clin Microbiol. 2011;51:83-85
48. Manyazewal T, Sisay Z, Biadgilign S., et al. Hepatitis B and hepatitis C virus infections among antiretroviral-naive and -experienced HIV coinfected adults in Addis Abba, Ethiopia. Int J Infect Dis. 2012;16:96
49. Shimelis T, Torben W, Medhin G., et al. Hepatitis B virus infection among people attending the voluntary counselling and testing centre and anti-retroviral therapy clinic of St Paul's General Specialised Hospital, Addis Ababa, Ethiopia. Sex Transm Infect. 2008;84:37-41
50. Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS. 2008;22:1221-1222
51. Pirillo MF, Bassani L, Germinario EA., et al. Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol. 2007;79:1797-1801
52. Rusine J, Ondoa P, Asiimwe-Kateera B., et al. High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda. PLoS One. 2013;8:e63303
53. Mutwa PR, Boer KR, Rusine JB., et al. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda. Pediatr Infect Dis J. 2013; 32:246-251
54. Telatela SP, Matee MI, Munubhi EK. Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. BMC Public Health. 2007;7:338
55. Nagu TJ, Bakari M, Matee M, Hepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health. 2008;8:416
56. Patel P, Davis S, Tolle M., et al. Prevalence of hepatitis B and hepatitis C coinfections in an adult HIV centre population in Gaborone, Botswana. Am J Trop Med Hyg. 2011;85:390-394
57. Rabenau HF, Lennemann T, Kircher C., et al. Prevalence- and genderspecific immune response to opportunistic infections in HIV-infected patients in Lesotho. Sex Transm Dis. 2010;37:454-459
58. Andersson MI, Maponga TG, Ijaz S., et al. Cross sectional analysis of the prevalence and character of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant woemn in the Western Cape, South Africa. J Hepatol. 2012;56:S33
59. Di Bisceglie AM, Maskew M, Schulze D., et al. HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antivir Ther. 2010;15(3 pt B):499-503
60. Firnhaber C, Reyneke A, Schulze D., et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S AfrMed J. 2008;98:541-544
61. Hoffmann CJ, Dayal D, Cheyip M., et al. Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa. Int J STD AIDS. 2012;23:e10-e13
62. Boyles TH, Cohen K. The prevalence of hepatitis B infection in a rural South African HIV clinic. S Afr Med J. 2011;101:470-471
63. Lukhwareni A, Burnett RJ, Selabe SG., et al. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol. 2009;81:406-412
64. Kapembwa KC, Goldman JD, Lakhi S., et al. HIV, Hepatitis B, and Hepatitis C in Zambia. J Glob Infect Dis. 2011;3:269-274
65. De Paschale M, Manco MT, Belvisi L., et al. Prevalence of markers of hepatitis B virus infection or vaccination in HBsAg-negative subjects. Blood Transfus. 2012;10:344-350
66. Sangare L, Sombie R, Combassere AW., et al. Antenatal transmission of hepatitis B virus in an area of HIV moderate prevalence, Burkina Faso [in French]. Bull Soc Pathol Exot. 2009;102:226-229
67. Ilboudo D, Karou D, Nadembega WM., et al. Prevalence of human herpes virus-8 and hepatitis B virus among HIV seropositive pregnant women enrolled in the Mother-to-Child HIV Transmission Prevention Program at Saint Camille Medical Centre in Burkina Faso. Pak J Biol Sci. 2007; 10:2831-2837
68. Ilboudo D, Simpore J, Ouermi D., et al. Towards the complete eradication of mother-to-child HIV/HBV coinfection at Saint Camille Medical Centre in Burkina Faso, Africa. Braz J Infect Dis. 2010;14:219-224
69. Bado G, Penot P, N'Diaye MD., et al. Hepatitis B seroprevalence in HIVinfected patients consulting in a public day care unit in Bobo Dioulasso, Burkina Faso. Med Mal Infect. 2013;43:202-207
70. Ouermi D, Simpore J, Belem AM., et al. Co-infection of Toxoplasma gondii with HBV in HIV-infected and uninfected pregnant women in Burkina Faso. Pak J Biol Sci. 2009;12:1188-1193
71. Kouanfack C, Aghokeng AF, Mondain AM., et al. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon. Antivir Ther. 2012;17:321-326
72. Zoufaly A, Onyoh EF, Tih PM., et al. High prevalence of hepatitis B and syphilis co-infections among HIV patients initiating antiretroviral therapy in the north-west region of Cameroon. Intl J STD AIDS. 2012;23: 435-438
73. Onyoh EF. High Prevalence of Hepatitis B and syphilis co-infection among newly diagnosed HIV patients in the northwest region of Cameroon. Trop Med Int Health. 2012;17:12
74. Jobarteh M, Malfroy M, Peterson I., et al. Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J. 2010;7:230
75. Sagoe KW, Agyei AA, Ziga F., et al. Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naive patients with HIV infection at a major treatment center in Ghana. J Med Virol. 2012; 84:6-10
76. Geretti AM, Patel M, Sarfo FS., et al. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol. 2010;48:3223-3230
77. Obi RK, Nwanebu FC, Ohalete CN., et al. A prospective study of three blood-borne viral pathogens among pregnant women attending ante-natal care in Owerri, Nigeria. J Public Health Epidemiol. 2012;4:226-229
78. Salami T, Babatope I, Adewuyi G., et al. Hepatitis B and HIV co-infection-experience in a rural/suburban health center in Nigeria. J Microbiol Biotechnol Res. 2012;2:841-844
79. Okocha EC, Oguejiofor OC, Odenigbo CU., et al. Prevalence of hepatitis B surface antigen seropositivity among HIV-infected and non-infected individuals in Nnewi, Nigeria. Niger Med J. 2012;53:249-253
80. Adekunle AE, Oladimeji AA, Temi AP., et al. Baseline CD4+ T lymphocyte cell counts, hepatitis B and C viruses seropositivity in adults with Human Immunodeficiency Virus infection at a tertiary hospital in Nigeria. Pan Afr Med J. 2011;9:6
81. Sadoh AE, Sadoh WE. Some laboratory features of HIV infected Nigerian children co-infected with heaptitis B and C. Ann Biomed Sci. 2012;11:29-39
82. Anigilaje EA, Olutola A. Prevalence and Clinical and Immunoviralogical Profile of Human Immunodeficiency Virus-Hepatitis B Coinfection among Children in an Antiretroviral Therapy Programme in Benue State, Nigeria. ISRN Pediatr. 2013;2013:932697
83. Tremeau-Bravard A, Ogbukagu IC, Ticao CJ., et al. Seroprevalence of hepatitis B and C infection among the HIV-positive population in Abuja, Nigeria. Afr Health Sci. 2012;12:312-317
84. Adesina O, Oladokun A, Akinyemi O., et al. Human immuno-deficiency virus and hepatitis B virus coinfection in pregnancy at the University College Hospital, Ibadan. Afr J Med Med Sci. 2010;39:305-310
85. Lesi OA, Kehinde MO, Oguh DN., et al. Hepatitis B and C virus infection in Nigerian patients with HIV/AIDS. Niger Postgrad Med J. 2007;14: 129-133
86. Adewole OO, Anteyi E, Ajuwon Z., et al. Hepatitis B and C virus coinfection in Nigerian patients with HIV infection. J Infect Dev Ctries. 2009;3:369-375
87. Otegbayo JA, Taiwo BO, Akingbola TS., et al. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol. 2008;7:152-156
88. Olokoba A, Olokoba L, Salawu F., et al. Hepatitis B virus and human immunodeficiency virus co-infection in North-Eastern Nigeria. Int J Trop Med. 2008;34:73-75
89. Balogun TM, Emmanuel S, Ojerinde EF. HIV, Hepatitis B and C viruses' coinfection among patients in a Nigerian tertiary hospital. Pan Afr Med J. 2012;12:100
90. Diop-Ndiaye H, Toure-Kane C, Etard JF., et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol. 2008;80:1332-1336
91. Garrido C, Trevino A, Bautista J., et al. High rate of chronic hepatitis B, overt and occult, in a virological survey of hepatitis viruses and human retroviruses in Ghana. Antivir Ther. 2011;15:1029-1034
92. N'Dri-Yoman T, Anglaret X, Messou E., et al. Occult HBV infection in untreated HIV-infected adults in Cote d'Ivoire. Antivi Ther. 2010;15: 1029-1034
93. Araujo NM, Branco-Vieira M, Silva AC., et al. Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters. Hepatol Res. 2008;38:1194-1203
94. Barth RE, Huijgen Q, Tempelman HA., et al. Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa. J Med Virol. 2011;83:929-934
95. Mphahlele MJ, Lukhwareni A, Burnett RJ., et al. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Microbiol. 2006;35:14-20
96. Bell TG, Makondo E, Martinson NA., et al. Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt-that is the question. PLoS One. 2012;7:e45750
97. Tenney DJ, Rose RE, Baldick CJ., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na've patients is rare through 5 years of therapy. Hepatology. 2009;49:1503-1514
98. Kitrinos KM, Corsa A, Liu Y., et al. No detectable resistance to tenofovir fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59:432-442